Mysildecard (Sildenafil)

Sildenafil, the active ingredient in Mysildecard, is a phosphodiesterase type 5 inhibitor presented as an oral tablet for oral use. It treats erectile dysfunction and pulmonary arterial hypertension in adult patients, improving vascular smooth‑muscle relaxation and blood flow in the corpus cavernosum and pulmonary arteries.

GNH USA supplies Mysildecard as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics, ensuring timely delivery and adherence to local pharmacopeial standards.

Mysildecard (sildenafil) is a selective phosphodiesterase‑5 inhibitor that modulates the nitric‑oxide/cGMP pathway, and it is clinically employed for disorders where enhanced vasodilation provides therapeutic benefit.

Erectile dysfunction: enhances erectile response by increasing blood flow to the penis, helping adult men achieve and sustain satisfactory erections during sexual activity. Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity by relaxing pulmonary vascular smooth muscle, benefiting patients with WHO Group 1 PAH. Diabetes‑related erectile dysfunction: improves erectile capacity in men with type 2 diabetes by the same mechanism of enhanced penile blood flow.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: transient warmth and redness of the face or upper chest. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: stuffy nose or runny nose. - Visual disturbances: blurred vision or a blue‑tinted visual field. - Back pain: muscle aches, typically in the lower back.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring urgent medical attention. - Sudden vision loss: abrupt loss of vision in one or both eyes, possibly indicating non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: rapid decrease or loss of hearing, sometimes accompanied by tinnitus. - Severe hypotension: marked drop in blood pressure, especially when combined with nitrates. - Allergic reactions: rash, itching, swelling, or anaphylaxis in rare cases.

Before initiating therapy, consider the following precautions: - Cardiovascular assessment: evaluate for recent myocardial infarction, unstable angina, or severe heart failure. - Nitrate use: avoid concurrent use with any nitrate medication due to risk of profound hypotension. - Alpha‑blocker therapy: use with caution as combined effect may cause excessive blood pressure drop. - Visual or auditory symptoms: discontinue use and seek medical evaluation if sudden loss occurs. - Dosage adherence: do not exceed the prescribed amount or frequency. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture and direct sunlight.

Sildenafil may interact with several medicines; monitor patients accordingly.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): concurrent use can cause severe hypotension. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect may lead to dangerous blood pressure drops. - Certain alpha‑adrenergic blockers: combined use may result in marked hypotension.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase sildenafil plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness. - Antihypertensive agents: concurrent therapy may enhance blood‑pressure‑lowering effects, requiring dose adjustments.